Aripiprazole

Generic Name: Aripiprazole

Brand Names: Abilify, Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen), Abilify Maintena, Aripiprazole Accord, Aripiprazole Sandoz, Aripiprazole Zentiva

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₇Cl_₂N_₃O_₂

CAS Number: 129722-12-9

Unique Ingredient Identifier: 82VFR53I78

Background: Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A receptors and antagonism of alpha-adrenergic and 5-HT2A receptors. Aripiprazole was given FDA approval on November 15, 2002.

Indication: Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette's disorder. It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation associated with schizophrenia or bipolar mania. Finally, an extended-release, bimonthly injection formulation of aripiprazole is indicated for the treatment of adult schizophrenia and maintenance therapy for adult bipolar I disorder.

Associated Conditions: Agitation, Bipolar 1 Disorder, Irritability, Major Depressive Disorder (MDD), Mixed manic depressive episode, Psychosis, Psychotic Depression, Schizophrenia, Tourette's Disorder (TD), Acute Manic episode

Associated Therapies: Monotherapy

Clinical Trials

Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)

Phase 4

Completed

Conditions: Autistic Disorder

Interventions: Drug: Risperidone
Drug: Aripiprazole

First Posted Date: 2011-04-11

Last Posted Date: 2018-09-26

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 80

Registration Number: NCT01333072

Locations: 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients

Phase 3

Terminated

Conditions: Schizophrenia

Interventions: Drug: LY2140023
Drug: Aripiprazole

First Posted Date: 2011-04-04

Last Posted Date: 2022-09-07

Lead Sponsor: Denovo Biopharma LLC

Target Recruit Count: 678

Registration Number: NCT01328093

Locations: 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malmo, Sweden

Aripiprazole Effects on Alcohol Drinking and Craving

Phase 3

Completed

Conditions: Alcohol Dependence

Interventions: Drug: Placebo
Drug: Aripiprazole

First Posted Date: 2011-02-09

Last Posted Date: 2017-08-08

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 99

Registration Number: NCT01292057

Locations: 🇺🇸
Medical University of South Carolina, Institute of Psychiatry, Center for Drug and Alcohol Programs, Charleston, South Carolina, United States

Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder

Phase 4

Completed

Conditions: Irritability Associated With Autistic Disorder

Interventions: Drug: Placebo
Drug: Aripiprazole

First Posted Date: 2010-10-25

Last Posted Date: 2014-05-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 215

Registration Number: NCT01227668

Locations: 🇺🇸
Childrens Specialty Gr., Pllc, Norfolk, Virginia, United States
🇺🇸
Stony Brook University School Of Medicine, Stony Brook, New York, United States
🇺🇸
Children'S Specialized Hosp, Toms River, New Jersey, United States

and more 35 locations

Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital

Phase 4

Withdrawn

Conditions: Schizophrenia

Interventions: Drug: haloperidole
Drug: perphenazine
Drug: paliperidone palmitate
Drug: olanzapine
Drug: paliperidone
Drug: aripiprazole
Drug: risperidone
Drug: quetiapine

First Posted Date: 2010-09-01

Last Posted Date: 2013-07-08

Lead Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC

Registration Number: NCT01193166

Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects

Phase 4

Completed

Conditions: Cytochrome P-450 CYP2D6
CYP3A4 Protein, Human
Pharmacokinetics

Interventions: Drug: Aripiprazole
Drug: Aripiprazole + desvenlafaxine succinate sustained release

First Posted Date: 2010-08-25

Last Posted Date: 2011-11-06

Lead Sponsor: Pfizer

Target Recruit Count: 38

Registration Number: NCT01188668

Locations: 🇺🇸
Pfizer Investigational Site, Miami, Florida, United States

Evaluation of Negative Symptoms and Cognitive Function After Administration of Antipsychotics in Healthy Volunteer

Completed

Conditions: Normal Volunteers

Interventions: Drug: risperidone
Drug: aripiprazole
Drug: haloperidol
Drug: amisulpride
Drug: lactose

First Posted Date: 2010-08-20

Last Posted Date: 2010-08-20

Lead Sponsor: Chonbuk National University Hospital

Target Recruit Count: 80

Registration Number: NCT01185418

Locations: 🇰🇷
Chonbuk national university hospital, Jeonju, Korea, Republic of

Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia

Phase 4

Completed

Conditions: Schizophrenia

Interventions: Drug: Olanzapine
Drug: Flupentixol
Drug: Haloperidol
Drug: Quetiapine
Drug: Aripiprazole

First Posted Date: 2010-07-16

Last Posted Date: 2015-06-22

Lead Sponsor: University of Bremen

Target Recruit Count: 149

Registration Number: NCT01164059

Locations: 🇩🇪
Klinikum Bremen-Ost gGmbH, Bremen, Germany
🇩🇪
Rheinische Kliniken Düsseldorf der Heinrich-Heine-Universität, Düsseldorf, Germany
🇩🇪
Privat-Nerven-Klinik Dr. med. Kurt Fontheim, Liebenburg, Germany

and more 15 locations